Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Solid Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Kung FH et al Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study Cancer 1993 Mar 1;71(5):1898-903
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26762
    Study title: Kung FH et al, Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of, childhood: a Pediatric Oncology Group Phase I/II study, J Pediatr Hematol Oncol. 1995 Aug;17(3):265-9
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26948
    Study title: Kung FH et al, Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study, Cancer 1993 Mar 1;71(5):1898-903
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26816
    Study title: Pratt CB et al Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience.Med Pediatr Oncol 1996 Sep;27(3):145-8
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26759
    Study title: Pratt CB et al, Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience., Med Pediatr Oncol 1996 Sep;27(3):145-8
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26813
    Study title: Loss JF et al Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil Pediatr Blood Cancer 2004 Feb;42(2):139-44
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26755
    Study title: Loss JF et al, Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil, Pediatr Blood Cancer 2004 Feb;42(2):139-44
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26809
    Study title: Kung FH et al Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study Cancer 1993 Mar 1;71(5):1898-903Kung FH et al Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study Cancer 1993 Mar 1;71(5):1898-903
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 24971
    Study title: Pratt CB et al Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study Invest New Drugs. 1986;4(1):43-8Pratt CB et al Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study Invest New Drugs. 1986;4(1):43-8
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25073
    Study title: Loss JF et al Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil Pediatr Blood Cancer 2004 Feb;42(2):139-44Loss JF et al Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil Pediatr Blood Cancer 2004 Feb;42(2):139-44
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 24989
    Study title: Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Pratt CB et al. Cancer. November 4, 1994, 2593-8
    Active substance: FLUOROURACIL
    Study summary document link (including results):
    View full study record
    Document reference: 28287
    Study title: Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Pratt CB et al. Cancer. November 4, 1994, 2593-8
    Active substance: FLUOROURACIL
    Study summary document link (including results):
    View full study record
    Document reference: 28298
    Study title: Phase II trial of ifosfamode with mesna in patients with pediatric malignant solid tumors (Pratt, C.B. Et al.-Proc.Ann. Meet.Am.Soc.Clin.Oncol.4 1985: Abstr. C-912)Phase II trial of ifosfamode with mesna in patients with pediatric malignant solid tumors (Pratt, C.B. Et al.-Proc.Ann. Meet.Am.Soc.Clin.Oncol.4 1985: Abstr. C-912)
    Active substance: MESNA
    Study summary document link (including results):
    View full study record
    Document reference: 31648
    Study title: Pratt CB et al Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study Invest New Drugs. 1986;4(1):43-8Pratt CB et al Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study Invest New Drugs. 1986;4(1):43-8
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32078
    Study title: Pratt CB et al Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study Invest New Drugs. 1986;4(1):43-8Pratt CB et al Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study Invest New Drugs. 1986;4(1):43-8
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32086
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 02:18:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA